Table 3 Association of osteoprotegerin (OPG) with different outcomes in three statistical models in the GCKD study

From: Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort

Outcomes

 

Univariate (Model 1)

Model 2

Model 3

  

HR [95% CI limits]

Non-CV death

387/4 245

HR per SD increase

3.73 [3.04; 4.57]

1.98 [1.53; 2.57]

1.76 [1.35; 2.30]

 

Q1

1 (ref.)

1 (ref.)

1 (ref.)

 

Q2

1.53 [1.00; 2.35]

1.18 [0.77; 1.83]

1.13 [0.73; 1.75]

 

Q3

1.91 [1.26; 2.88]

1.10 [0.72; 1.69]

0.96 [0.63; 1.48]

 

Q4

2.68 [1.81; 3.97]

1.27 [0.84; 1.91]

1.12 [0.74; 1.69]

 

Q5

5.02 [3.47; 7.26]

1.86 [1.25; 2.76]

1.50 [1.00; 2.26]

CV death

173/4 245

HR per SD increase

4.44 [3.32; 5.95]

2.37 [1.65; 3.40]

2.18 [1.50; 3.16]

 

Q1

1 (ref.)

1 (ref.)

1 (ref.)

 

Q2

1.55 [0.70; 3.45]

1.23 [0.54; 2.76]

1.22 [0.54; 2.77]

 

Q3

3.76 [1.87; 7.58]

2.16 [1.06; 4.40]

2.00 [0.97; 4.13]

 

Q4

3.85 [1.91; 7.76]

1.67 [0.81; 3.43]

1.66 [0.80; 3.44]

 

Q5

9.04 [4.67; 17.48]

3.26 [1.64; 6.49]

2.96 [1.47; 5.96]

MACE

645/4 244

HR per SD increase

2.71 [2.29; 3.21]

1.48 [1.20; 1.82]

1.38 [1.12; 1.71]]

 

Q1

1 (ref.)

1 (ref.)

1 (ref.)

 

Q2

1.59 [1.16; 2.17]

1.30 [0.94; 1.79]

1.26 [0.91; 1.75]

 

Q3

2.30 [1.72; 3.09]

1.45 [1.07; 1.97]

1.42 [1.04; 1.94]

 

Q4

2.20 [1.64; 2.97]

1.08 [0.79; 1.48]

1.04 [0.75; 1.43]

 

Q5

4.09 [3.10; 5.40]

1.86 [1.37; 2.51]

1.70 [1.25; 2.32]

CHF

368/4 245

HR per SD increase

3.66 [2.96; 4.53]

2.19 [1.68; 2.85]

2.05 [1.56; 2.69]

 

Q1

1 (ref.)

1 (ref.)

1 (ref.)

 

Q2

1.94 [1.23; 3.08]

1.52 [0.95; 2.43]

1.48 [0.92; 2.37]

 

Q3

2.66 [1.72; 4.12]

1.43 [0.91; 2.25]

1.35 [0.86; 2.13]

 

Q4

3.25 [2.12; 4.99]

1.47 [0.94; 2.28]

1.38 [0.88; 2.16]

 

Q5

6.14 [4.08; 9.22]

2.63 [1.72; 4.02]

2.43 [1.58; 3.76]

  1. The results are presented as hazard ratios with 95% confidence intervals given in parentheses
  2. Model 2: adjusted for age, sex, BMI, systolic blood pressure, LDL cholesterol, diabetes mellitus, eGFR, CVD, UACR, smoking, CRP, serum albumin, use of statins, use of RASis, use of thrombocyte aggregation inhibitors, use of beta blockers, use of aldosterone antagonists, and vitamin D therapy. Model 3: adjusted for parameters as in Model 2 plus BAP, calcium, phosphate, P1NP, CTX1, FGF23, 25-OH vitamin D, and iPTH
  3. OPG osteoprotegerin, ref. reference, HR hazard ratio, CI confidence interval, MACE major adverse cardiac event, CHF hospitalization due to congestive heart failure, BAP bone alkaline phosphatase, P1NP procollagen I intact N-terminal propeptide, CTX1 C-telopeptide of type 1 collagen, FGF23 fibroblast growth factor-23, iPTH intact parathyroid hormone
Back to article page